cbdMD (YCBD) Gains from Investment Securities (2019 - 2024)
cbdMD (YCBD) reported Gains from Investment Securities of -$4828.0 for Q1 2024, up 89.94% on a YoY basis from -$2541.8 in Q2 2023, and up 93.08% sequentially from -$69752.0 in Q4 2023.
cbdMD (YCBD) Gains from Investment Securities (2019 - 2024) Analysis & Trends
cbdMD (YCBD) has 6 years of Gains from Investment Securities data on file, last reported at -$4828.0 in Q1 2024.
- For the quarter ending Q1 2024, Gains from Investment Securities rose 89.94% year-over-year to -$4828.0; the trailing twelve-month figure through Dec 2024 stood at -$4828.0 (up 97.52% YoY), and the FY2024 full-year result was -$74580.0, up 59.83% from the prior year.
- Gains from Investment Securities rose to -$4828.0 in Q1 2024, from -$69752.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $8.9 million in Q1 2021 to a low of -$21.3 million in Q1 2020.
- A 5-year average of -$1.6 million and a median of -$69752.0 in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities jumped 150.3% in 2020 and slumped 170.0% in 2021, its largest moves.
- Tracing YCBD's Gains from Investment Securities over 5 years: stood at $8.5 million in 2020, then tumbled by 170.0% to -$5.9 million in 2021, then jumped by 98.97% to -$61000.0 in 2022, then decreased by 14.35% to -$69752.0 in 2023, then jumped by 93.08% to -$4828.0 in 2024.
- Business Quant data shows YCBD's Gains from Investment Securities at -$4828.0 in Q1 2024, -$69752.0 in Q4 2023, and -$31867.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | cbdMD | 4.60 Mn | 1.22 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -4,828.00 |
| Mar 31, 2024 | -4,828.00 |
| Dec 31, 2023 | -69,752.00 |
| Dec 31, 2023 | -69,752.00 |
| Sep 30, 2023 | -31,867.00 |
| Sep 30, 2023 | -31,867.00 |
| Jun 30, 2023 | -44,771.00 |
| Jun 30, 2023 | -44,771.00 |
| Mar 31, 2023 | -48,000.00 |
| Mar 31, 2023 | -48,000.00 |
| Dec 31, 2022 | -61,000.00 |
| Dec 31, 2022 | -61,000.00 |
| Sep 30, 2022 | -227,999.00 |
| Sep 30, 2022 | -227,999.00 |
| Jun 30, 2022 | -1.94 Mn |
| Jun 30, 2022 | -1.94 Mn |
| Mar 31, 2022 | -353,000.00 |
| Mar 31, 2022 | -353,000.00 |
| Dec 31, 2021 | -5.95 Mn |
| Dec 31, 2021 | -5.95 Mn |